These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 33551392)
1. Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention. Zhang Q; Hu M; Ma S J Atheroscler Thromb; 2021 Dec; 28(12):1289-1297. PubMed ID: 33551392 [TBL] [Abstract][Full Text] [Related]
2. The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Somuncu MU; Akgun T; Cakır MO; Akgul F; Serbest NG; Karakurt H; Can M; Demir AR J Atheroscler Thromb; 2019 Nov; 26(11):970-978. PubMed ID: 30996145 [TBL] [Abstract][Full Text] [Related]
3. The relationship between neutrophil counts on admission and angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Wang Z; Ren L; Lei L; Ye H; Peng J Acta Cardiol; 2016 Apr; 71(2):241-6. PubMed ID: 27090048 [TBL] [Abstract][Full Text] [Related]
4. Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP. Yu J; Oh PC; Kim M; Moon J; Park YM; Lee K; Suh SY; Han SH; Byun K; Ahn T; Kang WC PLoS One; 2017; 12(8):e0182829. PubMed ID: 28796845 [TBL] [Abstract][Full Text] [Related]
5. Soluble ST2 in plasma is associated with post-procedural no-or-slow reflow after primary percutaneous coronary intervention in ST-elevation myocardial infarction. Søndergaard FT; Beske RP; Frydland M; Møller JE; Helgestad OKL; Jensen LO; Holmvang L; Goetze JP; Engstrøm T; Hassager C Eur Heart J Acute Cardiovasc Care; 2023 Jan; 12(1):48-52. PubMed ID: 36355574 [TBL] [Abstract][Full Text] [Related]
6. Vitamin D level predicts angiographic no-reflow phenomenon after percutaneous coronary intervention in patients with ST segment elevation myocardial infarction. Şen Ö; Şen SB; Topuz AN; Topuz M Biomark Med; 2021 Oct; 15(15):1357-1366. PubMed ID: 34533051 [No Abstract] [Full Text] [Related]
7. Usefulness of fibrinogen-to-albumin ratio to predict no-reflow and short-term prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Zhao Y; Yang J; Ji Y; Wang S; Wang T; Wang F; Tang J Heart Vessels; 2019 Oct; 34(10):1600-1607. PubMed ID: 30993442 [TBL] [Abstract][Full Text] [Related]
8. Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Celık T; Balta S; Demır M; Yıldırım AO; Kaya MG; Ozturk C; Demırkol S; Unlu M; Kılıc S; Aydın İ; Iyısoy A Cardiol J; 2016; 23(1):84-92. PubMed ID: 26503078 [TBL] [Abstract][Full Text] [Related]
9. Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction. Aggarwal P; Rekwal L; Sinha SK; Nath RK; Khanra D; Singh AP Ann Cardiol Angeiol (Paris); 2021 Jun; 70(3):136-142. PubMed ID: 33962782 [TBL] [Abstract][Full Text] [Related]
10. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. Abtan J; Wiviott SD; Sorbets E; Popovic B; Elbez Y; Mehta SR; Sabatine MS; Bode C; Pollack CV; Cohen M; Moccetti T; Laanmets P; Faxon D; Okreglicki A; Ducrocq G; Steg PG; Arch Cardiovasc Dis; 2021 Mar; 114(3):187-196. PubMed ID: 33518473 [TBL] [Abstract][Full Text] [Related]
12. New CHA Zhang QY; Ma SM; Sun JY BMC Cardiovasc Disord; 2020 Jul; 20(1):346. PubMed ID: 32711475 [TBL] [Abstract][Full Text] [Related]
13. Usefulness of Mean Platelet Volume-to-Lymphocyte Ratio for Predicting Angiographic No-Reflow and Short-Term Prognosis After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. Kurtul A; Acikgoz SK Am J Cardiol; 2017 Aug; 120(4):534-541. PubMed ID: 28633762 [TBL] [Abstract][Full Text] [Related]
14. Predictive Value of Soluble Growth Stimulator Gene 2 Protein for Coronary Slow Flow/No-Reflow in ST-Elevation Myocardial Infarction Patients Receiving Percutaneous Coronary Intervention. Chang SM; Yu YT; Luan B; Hou AJ; Wang Y J Interv Cardiol; 2022; 2022():9322460. PubMed ID: 35510149 [TBL] [Abstract][Full Text] [Related]
15. The relationship between atherogenic index of plasma and no-reflow in patients with acute ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention. Süleymanoğlu M; Rencüzoğulları İ; Karabağ Y; Çağdaş M; Yesin M; Gümüşdağ A; Çap M; Gök M; Yıldız İ Int J Cardiovasc Imaging; 2020 May; 36(5):789-796. PubMed ID: 31919706 [TBL] [Abstract][Full Text] [Related]
16. Novel predictors and adverse long-term outcomes of No-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Refaat H; Tantawy A; Gamal AS; Radwan H Indian Heart J; 2021; 73(1):35-43. PubMed ID: 33714407 [TBL] [Abstract][Full Text] [Related]
17. Association of galectin-3 and soluble ST2 with in-hospital and 1-year outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Tymińska A; Kapłon-Cieślicka A; Ozierański K; Budnik M; Wancerz A; Sypień P; Peller M; Maksym J; Balsam P; Opolski G; Filipiak KJ Pol Arch Intern Med; 2019 Nov; 129(11):770-780. PubMed ID: 31642446 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Pre-Infarction Angina Combined with Mean Platelet Volume to Lymphocyte Count Ratio for No-Reflow and Short-Term Mortality in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Chen X; Meng Y; Shao M; Zhang T; Han L; Zhang W; Zhang H; Hai H; Li G Med Sci Monit; 2020 Jan; 26():e919300. PubMed ID: 31949123 [TBL] [Abstract][Full Text] [Related]
20. The association of baseline N-terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non-ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study. He WF; Jiang L; Chen YY; Liu YH; Chen PY; Duan CY; Zeng LH; Fan HL; Wei XB; Guo W; Chen W; Li J; Li WS; Guo ZQ; Liu ZK; Tan N; Chen JY; He PC BMC Cardiovasc Disord; 2021 Apr; 21(1):202. PubMed ID: 33882836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]